Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Envoy Medical (COCH) EBITDA Margin (2022 - 2025)

Envoy Medical's EBITDA Margin history spans 4 years, with the latest figure at 8781.33% for Q4 2025.

  • Quarterly results put EBITDA Margin at 8781.33% for Q4 2025, up 221867.0% from a year ago — trailing twelve months through Dec 2025 was 9856.02% (down 61157.0% YoY), and the annual figure for FY2025 was 9856.02%, down 61157.0%.
  • EBITDA Margin for Q4 2025 was 8781.33% at Envoy Medical, up from 15435.71% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1952.5% in Q3 2023 to a low of 57405.0% in Q4 2022.
  • The 4-year median for EBITDA Margin is 10636.73% (2024), against an average of 12958.97%.
  • The sharpest move saw EBITDA Margin surged 5225026bps in 2023, then tumbled -1259714bps in 2024.
  • Year by year, EBITDA Margin stood at 57405.0% in 2022, then soared by 91bps to 5154.74% in 2023, then plummeted by -113bps to 11000.0% in 2024, then rose by 20bps to 8781.33% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 8781.33%, 15435.71%, and 7297.44% for Q4 2025, Q3 2025, and Q2 2025 respectively.